首页> 外文期刊>The American Journal of Cardiology >System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myocardial Infarction-2 (DANAMI-2) trial).
【24h】

System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myocardial Infarction-2 (DANAMI-2) trial).

机译:急性心肌梗塞的系统延迟和干预时机(来自丹麦急性心肌梗塞2(DANAMI-2)试验)。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The interval from the first alert of the healthcare system to the initiation of reperfusion therapy (system delay) is associated with mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (pPCI). The importance of system delay in patients treated with fibrinolysis versus pPCI has not been assessed. We obtained data on system delay from the Danish Acute Myocardial Infarction-2 study, which randomized 1,572 patients to fibrinolysis or pPCI. The study end points were 30-day and 8-year mortality. The short system delays were associated with reduced absolute mortality in both the fibrinolysis group (<1 hour, 5.6%; 1 to 2 hours, 6.9%; 2 to 3 hours, 9.5%; and >3 hours, 11.5%; test for trend, p = 0.08) and pPCI group (<1 hour, not assessed; 1 to 2 hours, 2.6%; 2 to 3 hours, 7.5%; >3 hours, 7.7%; test for trend, p = 0.02). The lowest 30-day mortality was obtained with pPCI and a system delay of 1 to 2 hours (vs fibrinolysis within <1 hour, adjusted hazard ratio 0.33; 95% confidence interval 0.10 to 1.10; p = 0.07; vs fibrinolysis within 1 to 2 hours, adjusted hazard ratio 0.37; 95% confidence interval 0.14 to 0.95; p = 0.04). pPCI and system delay >3 hours was associated with a similar 30-day and 8-year mortality as fibrinolysis within 1 to 2 hours. In conclusion, short system delays are associated with reduced mortality in patients with ST-segment elevation myocardial infarction treated with fibrinolysis as well as pPCI. pPCI performed with a system delay of <2 hours is associated with lower mortality than fibrinolysis performed with a faster or similar system delay.
机译:从医疗系统的第一次警报到开始再灌注治疗(系统延迟)的时间间隔与原发性经皮冠状动脉介入治疗(pPCI)治疗的ST段抬高型心肌梗死患者的死亡率相关。尚未评估纤维蛋白溶解和pPCI治疗患者系统延迟的重要性。我们从丹麦急性心肌梗塞2研究中获得了有关系统延迟的数据,该研究将1,572例患者随机分为纤维蛋白溶解或pPCI患者。研究终点为30天和8年死亡率。短暂的系统延迟与纤溶组的绝对死亡率降低相关(<1小时,5.6%; 1至2小时,6.9%; 2至3小时,9.5%;和> 3小时,11.5%;测试趋势,p = 0.08)和pPCI组(<1小时,未评估; 1至2小时,2.6%; 2至3小时,7.5%;> 3小时,7.7%;趋势测试,p = 0.02)。使用pPCI和系统延迟为1至2小时(相对于纤溶在<1小时之内,风险比调整为0.33; 95%置信区间为0.10至1.10; p = 0.07;相对于纤溶在1至2之内)获得的30天死亡率最低小时,调整后的危险比为0.37; 95%置信区间为0.14至0.95; p = 0.04)。 pPCI和系统延迟> 3小时与1-2小时内的纤维蛋白溶解相似的30天和8年死亡率相关。总之,短暂的系统延迟与经纤维蛋白溶解以及pPCI治疗的ST段抬高型心肌梗死患者的死亡率降低相关。与以较快或类似的系统延迟执行的纤维蛋白溶解相比,以2小时以下的系统延迟执行的pPCI与较低的死亡率相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号